2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.03E.01 Patient-Derived Organoids Can Predict Response to Chemotherapy and Targeted Thrapy in Lung Cancer Patients

EP.03E.01 Patient-Derived Organoids Can Predict Response to Chemotherapy and Targeted Thrapy in Lung Cancer Patients

Pdf Summary

The study explores the potential of patient-derived organoids (PDOs) to predict responses in lung cancer patients to chemotherapy and targeted therapies. Given the significant heterogeneity among individuals and the multitude of available therapeutic options, there's an acute need for reliable biomarkers to foresee treatment responses. The research involved isolating lung cancer cells from patients and culturing them to form lung cancer organoids (LCOs). These organoids were then subjected to pathohistologic validation, next-generation sequencing, and drug sensitivity testing to assess their responsiveness to different clinical drugs.<br /><br />Out of 60 patients undergoing standard care, the study successfully generated organoids for 54, representing around 90% success rate. The organoids included diverse histological subtypes and mutation types in alignment with the primary tumor tissues. Notably, the in-vitro drug sensitization results mirrored the clinical outcomes, demonstrating both inter- and intrapatient drug response variability.<br /><br />The findings revealed a correlation between the drug sensitivity of the organoids and the patients' clinical outcomes, including progression-free survival (PFS). This suggests that PDOs can effectively predict patient responses in clinical settings, offering a promising companion diagnostic tool. They can complement genetic testing and support the development of personalized treatment strategies for lung cancer, while enhancing understanding of genetic and drug response heterogeneity.<br /><br />Overall, this study highlights the potential of using PDOs to tailor lung cancer treatments, enable more informed decisions regarding therapeutic options, and improve patient outcomes by aligning treatment strategies with individual tumor characteristics.

Asset Subtitle

Chunyan Wang

Meta Tag

Speaker Chunyan Wang

Topic Tumor Biology – Translational Biology

Keywords

patient-derived organoids

lung cancer

chemotherapy

targeted therapies

biomarkers

drug sensitivity

personalized treatment

genetic testing

progression-free survival

tumor heterogeneity